Cd16a

Author:Prof. Dr. med. Peter Altmeyer

All authors of this article

Last updated on: 29.10.2020

Dieser Artikel auf Deutsch

Synonym(s)

Fcγ receptor IIIa; FcγRIIIα

Requires free registration (medical professionals only)

Please login to access all articles, images, and functions.

Our content is available exclusively to medical professionals. If you have already registered, please login. If you haven't, you can register for free (medical professionals only).


Requires free registration (medical professionals only)

Please complete your registration to access all articles and images.

To gain access, you must complete your registration. You either haven't confirmed your e-mail address or we still need proof that you are a member of the medical profession.

Finish your registration now

DefinitionThis section has been translated automatically.

CD 16a denotes a surface protein from the group of Fc-receptors (Fcγ-receptor IIIa). As Fcγ-receptor protein, CD16a binds with low affinity to the Fc region of immunoglobulin G (insofar as its designation as "low affinity immunoglobulin gamma Fc region receptor III-A", independent of the binding of antigens. The receptor protein Fcγ-receptor IIIa is encoded in humans by the FCGR3A gene, which is located on chromsome 1q23.

CD 16a is expressed on the surface of numerous immune cells, including NK cells, neutrophil granulocytes, monocytes and macrophages. CD16a plays a major role in antibody-dependent cellular cytotoxicity (ADCC). ADCC opens up a targeted immune moderation via a CD16-triggered cell-to-cell cytolytic approach, which could be applied not only in inflammatory diseases but also in various malignant tumors. Experimental approaches result with a bispecific anti-CD30/CD16A antibody (Wu J et al.2015).

LiteratureThis section has been translated automatically.

  1. Ochoa MC et al (2017) Antibody-dependent cell cytotoxicity: immunotherapy strategies enhancing effector NK cells. Immunol Cell Biol 95:347-355.
  2. van Sorge NM et al (2003) FcgammaR polymorphisms: Implications for function, disease susceptibility and immunotherapy.Tissue Antigen 61:189-202.
  3. Wu J et al (2015) AFM13: a first-in-class tetravalent bispecific anti-CD30/CD16A antibody for NK cell-mediated immunotherapy. J Hematol Oncol 8:96.

Authors

Last updated on: 29.10.2020